Shares of Belite Bio, Inc. Sponsored ADR (BLTE) have gained 2.5% over the past four weeks to close the last trading session at 40.03,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof56.50 indicates a potential upside of 41.1%.The average comprises four short-term price targets ranging from a low of 50toahighof60, with a standard deviation of $4.51. While the lowest esti ...